Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity

• Published in: The journal of clinical endocrinology and metabolism Vol. 96; no. 10; pp. E1568 - E1576
• Main Authors: Ooi, Esther M. M., Watts, Gerald F., Sprecher, Dennis L., Chan, Dick C., Barrett, P. Hugh R.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.10.2011; Copyright by The Endocrine Society
• Subjects: Adult; Agonists; Apolipoprotein A-I - blood; Apolipoprotein A-II - blood; Apolipoproteins; Apolipoproteins B - blood; Apolipoproteins C - blood; Blood; Cardiorespiratory; Cardiovascular diseases; Cholesterol; Cholesterol - blood; Cholesteryl ester transfer protein; Cross-Over Studies; Double-Blind Method; Dyslipidemia; Dyslipidemias - blood; High density lipoprotein; Humans; Kinetics; Lipid metabolism; Lipids; Lipids - blood; Lipoproteins; Lipoproteins (very low density); Lipoproteins - blood; Lipoproteins, HDL - blood; Lipoproteins, LDL - blood; Lipoproteins, VLDL - blood; Low density lipoprotein; Male; Measurement; Men; Metabolic disorders; Metabolism; Middle Aged; Obesity; Obesity, Abdominal - blood; Peroxisome proliferator-activated receptors; Placebos; PPAR delta - agonists; Proteins; Receptor density; Thiazoles - pharmacology; Triglycerides; Triglycerides - blood

Context:Dyslipidemia increases the risk of cardiovascular disease in obesity. Peroxisome proliferator-activated receptor (PPAR)-δ agonists decrease plasma triglycerides and increase high-density lipoprotein (HDL)-cholesterol in humans.Objective:The aim of the study was to examine the effect of GW501...